Prospective cohort study reveals MMP-9, a neuroplasticity regulator, as a prediction marker of cochlear implantation outcome in prelingual deafness treatment.

Monika Matusiak (✉ m.matusiak@ifps.org.pl)

Institute of Physiology and Pathology of Hearing, Warsaw   https://orcid.org/0000-0003-1138-3425

Dominika Oziębło

Institute of Physiology and Pathology of Hearing, Warsaw

Monika Ołdak

Institute of Physiology and Pathology of Hearing, Warsaw

Emilia Rejmak

Nencki Institute of Experimental Biology PAS: Instytut Biologii Doswiadczalnej im Marcelego Nenckiego Polskiej Akademii Nauk

Leszek Kaczmarek

Nencki Institute of Experimental Biology PAS: Instytut Biologii Doswiadczalnej im Marcelego Nenckiego Polskiej Akademii Nauk

Piotr Henryk Skarżyński

Institute of Physiology and Pathology of Hearing, Warsaw

Henryk Skarżyński

Institute of Physiology and Pathology of Hearing, Warsaw

Abstract

Because of vast variability of cochlear implantation outcomes in prelingual deafness treatment, identification of good and poor performers remains a challenging task. To address this issue, we investigated genetic variants of matrix metalloproteinase 9 (*MMP9*) and brain derived neurotrophic factor (*BDNF*) and plasma levels of MMP-9, BDNF, and pro-BDNF that have all been implicated in neuroplasticity after sensory deprivation in the auditory pathway. We recruited a cohort of prelingually deaf children, all implanted before the age of 2, and carried out a prospective observation (*N* = 61). Next, we analyzed the association between (i) functional *MMP9* (rs20445, rs1839242, rs2234681) and *BDNF* (rs6265) gene variants (and their respective protein levels) and (ii) the child's auditory development as measured with the LittlEARS Questionnaire (LEAQ) before cochlear implant (CI) activation and at 8 and 18 months post-CI activation. Statistical analyses revealed that the plasma level of MMP-9 measured at implantation in prelingually deaf children was significantly correlated with the LEAQ score 18 months after CI activation. In the subgroup of DFNB1-related deafness (*N* = 40), rs3918242 of *MMP9* was significantly associated with LEAQ score at 18 months after CI activation; also, according to a multiple regression model, the ratio of plasma levels of pro-BDNF/BDNF measured at implantation was a significant predictor of overall LEAQ score at follow-up. In the subgroup with DFNB1-related deafness, who had CI activation after 1 year old (*N* = 22), a multiple regression model showed that rs3918242 of *MMP9* was a significant predictor of overall LEAQ score at follow-up.

1. Introduction

1.1 Congenital deafness treatment with cochlear implantation and variability of its outcome

Congenital deafness is a disabling condition which, untreated, has far-reaching consequences and profoundly affects the quality of the patient's life. Cochlear implants (CIs), neuroprostheses commonly used in treating the disease are a very effective tool for restoring absent auditory function. However, despite the undeniable success of the method, one caveat is a large degree of variability in outcomes across individual CI users. Beside the very good performers, who develop speech and language almost normally, some implanted children, despite great effort at rehabilitation, never reach age-appropriate proficiency in speech, language, and verbal communication [1-3]. For clinicians, it is difficult to pre-operatively predict how well an individual patient will perform with a CI. Only a part of the variance in performance can be accounted for by known factors, such as age of implantation, etiology of hearing loss, existence of comorbidities, and others [1-12].

In over 50% of cases, a genetic etiology of deafness has been confirmed by mutations in the *GJB2* and *GJB6* genes in the DFNB1 *locus* [6]. The presence of pathogenic variants in the DFNB1 *locus* causes malfunctioning of the organ of Corti, although the molecular mechanism behind it is still under investigation [6,13,14]. Delivery of electrical stimulation to the auditory pathway involves an interplay between implant software and brain tissue (wetware) [1,4]. For this reason, it is thought that the missing factors contributing to CI outcome, which might also serve as either biochemical or genetic biomarkers

of auditory development following a CI, could be located in the biological environment of the implant [4]. Finding such biomarkers would be important, as it would allow increased efforts to be made in identifying children at risk of failure of their CI.

1.2 Neuronal plasticity

The cerebral cortex of a developing child responds to sensory stimuli coming from the child's environment by undergoing neuronal plasticity [15,1,16]. The ability to modify the strength and efficacy of cortical synapses is the neurons' essential attribute, and is needed for learning and memory, but in an aberrant form it contributes to many pathological conditions such as addiction, schizophrenia, or epilepsy [1,16-19]. The recent introduction of the tetrapartite synapse concept has drawn attention to the extracellular matrix (ECM) as a factor contributing to synapse function and dysfunction [17]. The ECM might be cleaved by matrix metalloproteinases (MMPs), making it particularly susceptible to remodeling processes [17,18,20-23]. MMPs are a family of metzincin proteinases with a well-established role in developmental plasticity – well-documented in the case of MMP-9 [20,21]. Experimental data demonstrate that MMP-9 is a critical factor in late phase Long Term Potentiation (LTP), which is considered the physiological basis of synaptic plasticity [24-27]. It has also been postulated, based on research on rodent models, that MMP-9 is involved in plasticity during critical periods in development by regulating synaptogenesis, axonal growth, and myelination [20)]. Furthermore, genetic association studies have supported the role of MMP-9 in a series of brain disorders involving aberrant plasticity [17,19,28]. BDNF is another protein of pivotal importance in neuronal plasticity [29,30]. The molecule can potentiate synaptic transmission, thus inducing LTP, and is tightly connected with cognitive processes, memory, and learning [29,31,32]. Interestingly, the protein might be cleaved from pro-BDNF into a mature BDNF form (BDNF) by MMP-9 [29,32-36].

Given the reported role of both MMP-9 and BDNF in neuronal plasticity, it may be beneficial to study their roles in auditory plasticity after a child with congenital deafness receives a CI. For this reason, we have designed an association study between polymorphisms known to affect *MMP9* and *BDNF* expression and auditory development as measured by the score of parental LEAQ. The study was performed in a group of deaf infants and toddlers implanted with the same type of device. We have also searched for associations among plasma levels of MMP-9, BDNF collected at cochlear implantation, and pro-BDNF/BDNF ratio and the children's auditory development.

1.3 Aim of the study

In this study we wanted to test the hypothesis that carrying a specific set of functional *MMP9* and *BDNF* gene variants, and protein plasma levels of MMP-9, BDNF, and pro-BDNF/BDNF ratio, measured at cochlear implantation, can serve as prognostic biomarkers of functional outcomes of CI treatment in a population of congenitally deaf children. To verify this assumption, we collected a dataset from a cohort of 70 implanted infants and toddlers. To our knowledge, the role of *MMP9* and *BDNF* genes together with their proteins in the neuroplasticity of the human auditory system has not been explored so far.

2. Material And Methods

2.1 Study design, participants, and ethical approval

This prospective cohort study was done between December 2016 and December 2019 in the Institute of Physiology and Pathology of Hearing in Warsaw, Poland. We recruited infants and toddlers with hearing loss, who underwent cochlear implantation with the same type of device, performed by the same surgeon, and who all had their speech processor activated before the age of 2. Inclusion criteria were congenital bilateral profound sensorineural hearing loss, confirmed by auditory brainstem responses (ABR). Exclusion criteria were the presence of any acute inflammation confirmed by CRP (C-reactive protein) measurements and the presence of environmental risk factors, such as chronic concomitant disease, severe prematurity, asphyxia, or history of viral infection during pregnancy. After activation of the CI, parents or caregivers followed instructions of auditory–verbal therapy. Children were clinically assessed for auditory development by using the LEAQ before CI activation and at the 8th and 18th month after CI activation (LEAQ_0, LEAQ_8, LEAQ_18). Additionally, at cochlear implantation patients had their blood sampled for polymorphisms testing and MMP-9, BDNF, pro-BDNF, and CRP plasma level (MMP-9_0, BDNF_0, pro-BDNF_0). Out of 70 children enrolled in the study, one patient was excluded due to autism spectrum disorder diagnosed during follow-up (and therefore assessed as having unreliable auditory development); two cases were excluded due to the parents withdrawing from the study; and six patients were excluded due to elevated CRP levels. LEAQ scores were successfully collected from all participants at all three intervals. Demographic data were also obtained. Participants underwent genetic testing of the DFNB1 *locus*, and were classified into two subgroups: DFNB1-related deafness and not DFNB1-related deafness. Following the line of maximal homogeneity, patients with DFNB1-related deafness were divided into subgroups according to their age at CI activation: "CI activation before 1 year old", and "CI activation after 1 year old".

2.2 Auditory development assessment

Participants were assessed for their auditory development by the LEAQ, which is designed to assess auditory development in very young children [37]. LEAQ consists of 35 questions with a "yes" or "no" answer. The total score is the number of "yes" answers. The LEAQ has been validated in over 20 languages (38 - 43).

2.3 Genotyping

The *MMP9* polymorphism rs3918242 (NM_004994.2:c.-1590C>T) was genotyped using the PCR-RFLP method. The genomic region encompassing rs3918242 was amplified using forward 5'-GCCTGGCACATAGTAGGCCC-3' and reverse 5'-CTTCCTAGCCAGCCGGCATC-3' primers (Oligo IBB PAN, Warsaw, Poland) and the PCR product was digested with the PaeI restriction enzyme (Thermo Fisher Scientific, Waltham, MA, USA). The allele containing reference variant C was represented by a DNA band of size 435 bp and the allele containing alternative variant T was represented by bands of sizes 188 and 247 bp.

Genotyping of *MMP9* polymorphism rs2234681 (13–26 CA repeats around NM_004994.2:c.-90) included amplification with forward 5'-FAM-CTGAGGGCCTGCGGTTTCCT3' and reverse 5'CCTTGACAGGCAAGTGCTGACT3' primers (Oligo IBB PAN). PCR products were separated by capillary electrophoresis on a 3500xL Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Results were analyzed with GeneMapper v4.1 Software (Applied Biosystems) and reported as either less than 20 CA repeats (<20) or equal to or more than 20 CA repeats (≥20).

The *MMP9* polymorphism rs20544 (NM_004994.2:c.*3C>T) and the *BDNF* polymorphism rs6265 (NM_170735.5:c.196G>A) were genotyped using predesigned TaqMan SNP genotyping assays (Applied Biosystems) and a real-time PCR system (Viia7, Thermo Fisher Scientific).

The accuracy of genotyping was confirmed by Sanger sequencing in randomly selected samples. The results were 100% concordant. Detailed genotyping conditions are available upon request.

2.4 Plasma sample collection

Blood samples were collected on heparin and centrifuged at 1400 g for 15 min. Next, plasma was obtained, aliquoted, and stored at −80°C for further analysis. Total protein content was measured with a BCA protein assay kit (Thermo-Scientific) following the manufacturer's protocol.

2.5 MMP-9, BDNF, and pro-BDNF plasma level measurements

Plasma concentrations of MMP-9, BDNF, and pro-BDNF were determined by ELISA (MMP-9 and BDNF − R&D Systems Inc., Minneapolis, USA; pro-BDNF − Aviscera Bioscience, Santa Clara, CA, USA) according to the manufacturer's protocol. A total of 30 µg/µl of protein from each plasma sample was diluted 70-fold (MMP-9) or 20-fold (BDNF and pro-BDNF) with calibration diluent from the assays and analyzed in duplicates. The optical density of wells was measured at 450 nm using an automated microplate reader (Sunrise Microplate Absorbance Reader).

2.6 Statistical analyses

2.6.1 Paired comparisons methodology

For all tested follow-up intervals (i.e. at the time of CI activation, and at the 8th and 18th month after CI activation) comparisons of mean LEAQ scores, BDNF levels, and MMP-9 levels were made between patients with different genotypes using a Welch two-sample *t*-test (if test assumptions were met) or the Wilcoxon rank-sum test. All calculations were performed with R (version 3.6.3). Results were considered statistically significant at a *p*-value ≤0.05.

2.6.2 Correlation analysis methodology

LEAQ scores measured at different time intervals from CI activation and BDNF, MMP-9 levels, and pro-BDNF/BDNF ratios measured at CI activation were tested for correlation and strength using a Pearson

test (if test assumptions were met) or a Spearman test. Prior to correlation tests, a Shapiro−Wilk test of normality was made in order to check assumptions. All variables for which the correlation was tested were normalized using the min-max scaling method. Correlations were considered statistically significant at p-value ≤0.05. All computations were made using R version 3.6.3 (2020).

2.6.3 Modelling methodology

To address the longitudinal aspect of the study design, linear mixed-effect models were built. BDNF, MMP-9, and pro-BDNF/BDNF ratio levels, as well as *BDNF* rs6265, *MMP9* rs3918242, MMP9 rs20544, and *MMP9* rs2234681 genotypes, sex, follow-up interval, and age at CI activation were included in the models as a set of predictors. Differences were considered statistically significant at $p \le 0.05$. All calculations were performed with R (version 3.6.3) and lme4, blme, stargazer, and lmerTest packages. Further details about the methodology can be found in our previous publication [44].

3. Results

3.1 Sample demographics and auditory development

In the group of 61 implanted children, 28 (45.9%) were girls and 33 boys (54.1%). The mean age at CI activation in the study group was 411.4 days (min = 208; max = 739; SD = 135.1). In 40 cases DFNB1-related deafness was identified. In this subgroup, 18 (45%) were girls and 22 were boys (55%). The mean age at CI activation in the subgroup was 407.7 days (min = 208, max = 654, SD = 128). All children were implanted with the Med-El Synchrony CI and became regular CI users. All participants were of Caucasian origin.

3.2 Genotyping

Distributions of genotypes were in the Hardy−Weinberg equilibrium in the whole studied cohort. For rs3918242 of *MMP9* gene, the C/C genotype was found in 43 cases (70.49%) and the C/T genotype in 18 cases (29.51%). For rs20544 of *MMP9* gene, the C/C genotype was found in 16 cases (26.23%), the C/T genotype in 29 cases (47.54%), and the T/T genotype in 16 (26.23%) cases. For rs2234681 of *MMP9* gene, the <20/<20 genotype was found in 17 cases (27.87%), the <20≥20 genotype in 34 cases (55.74%), and the ≥20/≥20 genotype in 10 cases (16.39%). For rs6265 of *BDNF* gene, the Val/Met genotype was found in 18 cases (29.51%) and the Val/Val genotype in 43 cases (70.49%).

3.3 MMP-9, BDNF, and pro-BDNF plasma levels

The mean value of protein plasma level for MMP-9_0 was 236.94 ng/ml and the levels varied from 31.14 to 769.67 (SD 135.59). Mean value of protein plasma level of BDNF_0 was 2.28 ng/ml, the levels varied from 0.25 to 12.17 (SD 1.91). Mean value of protein plasma levels of pro-BDNF_0 was 19.31, and the levels varied from 0.00 to 162.16 (SD 36.08). Mean value of pro-BDNF_0/BDNF_0 ratio was 15.02, and the values varied from 0.00 to 161.55 (SD 31.64).

3.4 Analyses in the study group

In the study group, no significant associations between *MMP9* and *BDNF* genetic variants and LEAQ score at any of the tested follow-up intervals (before CI activation, and at the 8th and 18th month after CI) were identified (data not shown).

We did not observe any significant correlations of the protein levels of MMP-9_0, BDNF_0, and pro-BDNF_0/BDNF_0 ratio with LEAQ_0 and LEAQ_8. Testing correlations between MMP-9_0, BDNF_0, and pro-BDNF_0/BDNF_0 ratio with LEAQ_18 showed a weak negative correlation between MMP-9_0 and LEAQ_18 score ($p<0.05$, rho = −0.25) (Fig. 1).

3.5 Analyses in the subgroup with DFNB1-related deafness

In the subgroup with DFNB1-related deafness, we identified a significant association between rs3918242 *MMP9* and LEAQ 18. No statistically significant associations were seen for the other tested polymorphisms at any of the follow-up intervals (Table 1).

There was no correlation between plasma levels of MMP-9_0 and BDNF_0 and pro-BDNF_0/BDNF_0 ratio with LEAQ_0 and LEAQ_8 in the DFNB1-related deafness subgroup.

A weak negative correlation was found between plasma levels of MMP-9_0 with LEAQ_18 in the DFNB1-related deafness subgroup ($p<0.01$, rho = −0.4) (Fig. 2). There was no correlation between BDNF_0 and pro-BDNF_0 /BDNF_0 ratio and LEAQ_18.

To build a linear mixed-effect model using plasma levels of the analyzed proteins as predictors for the subgroup with DFNB1-related deafness, observations for every patient were broken down into single measurements of language development (LEAQ score) from CI activation to the 18th month after CI activation. This gave a set of 120 observations. The model revealed that, apart from the follow-up interval, the pro-BDNF_0/BDNF_0 ratio is a significant predictor of auditory development. The average R^2 for the model was 0.72, indicating that it could explain a considerable level of variation in the data. The *p*-values of the predictor variables and their associated impact on global outcome scores are shown in Table 3. In a similar way, for the same subgroup we built a multiple regression model using the tested polymorphisms as predictors, and the model revealed that one significant predictor of auditory development was follow-up interval (data not shown).

To give a clinical interpretation of the impact of the significant predictor pro-BDNF_0/BDNF_0 ratio on auditory development, the regression coefficient shows that a decrease in the ratio of 20 (1:0.05) will, on average, result in an increase of LEAQ score of 1 point in an implanted child with DFNB1-related deafness.

3.6 Analyses in subgroups: DFNB1-related deafness and CI activation before and after 1 year

In none of the two DFNB1-related subgroups (CI < 1 or CI > 1 y. o.) did we find any significant association between the tested *MMP9* and *BDNF* genetic variants and LEAQ score at any of the tested follow-up intervals (data not shown).

In the subgroup with DFNB1-related deafness and CI activation after 1 year, no correlation between MMP-9_0 and LEAQ_0 was found, a positive correlation between BDNF_0 and LEAQ_0 score (p=0.03, Rho = 0.4) and a negative correlation was found between pro-BDNF_0/BDNF_0 ratio and LEAQ_0 score (p = 0.01, Rho = −0.5) were found. Testing between MMP-9_0, BDNF_0, and pro-BDNF_0/BDNF_0 ratio with LEAQ_8 did not show any correlation. For LEAQ_18 it showed a moderate negative correlation between MMP-9_0 and LEAQ_18 score (*p* = 0.01, rho = −0.5) and no correlation between BDNF_0 and pro-BDNF_0/BDNF_0 and LEAQ_18 (Fig. 3).

Similar analyses performed in the younger subgroup did not reach statistical significance.

For both younger and older subgroups, we built a linear mixed models on a set of 54 and 66 observations, respectively, with the tested polymorphisms as predictors. The model built for the older subgroup revealed that a significant predictor of auditory development outcome (LEAQ score), apart from the follow-up interval, is rs3918242 of *MMP9* (Table 3). The R^2 for the model was 0.7. The *p*-values of the predictor variables and their associated impact on global outcome scores are shown in Table 3. For the younger group, the model with tested polymorphisms as predictors revealed that the only significant predictor is the follow-up interval (data not shown). On the same sets of observations we built multiple regression models for both subgroups, using inclusion of plasma levels of analyzed proteins (measured at CI activation) as predictors. The models did not reveal statistical significance for any of the predictors, apart from follow-up interval (data not shown).

The regression coefficients show that an average patient who is a carrier of a C/C variant of rs3918242 of *MMP9* will score, on average, 6.49 points higher at any interval than a carrier of a C/T variant.

We have determined relations between mean values of plasma levels of the tested proteins and genetic variants. We did not find any statistically significant differences either in the study group or in the DFNB1-related deafness subgroup.

4. Discussion

The present report seems to be the first to identify molecular and genetic biomarkers of neuronal plasticity after restoration of an absent sensory function in humans. The study has investigated possible associations between functional variants of the *MMP9* and *BDNF* genes (and their products in plasma) and auditory development in congenitally deaf children after cochlear implantation. Our main findings can be summarized as follows. (i) Plasma level of MMP-9 protein measured at cochlear implantation in congenitally deaf children is significantly correlated with auditory development measurements (LEAQ score) at 18 months after the device activation. (ii) In the subgroup with DFNB1-related deafness, functional *MMP9* variant rs3918242 significantly impacts auditory development measured at the 18th

month after the device activation; it is also a significant predictor of overall LEAQ score in the subgroup with DFNB1-related deafness and activation after at the 1 year. (iii) The pro-BDNF/BDNF ratio measured at cochlear implantation is a significant predictor of auditory development (LEAQ score) as measured in the subgroup with DFNB-1 related deafness.

For this prospective cohort study, we enrolled children diagnosed with bilateral congenital deafness without any co-morbidities (and with non-contributory medical and pregnancy history). Patients were implanted with the same type of device, by the same experienced surgeon, and had their speech processor activated before 2nd birthday; they also received the same rehabilitation program and their auditory development was observed for 18 months after CI activation. The literature already indicates that etiological homogeneity, such as mutations in the DFNB1 *locus*, have a predictive value for cochlear implantation outcome [6,7,10-12]. Following this lead, our analyses focused on the subgroup of children with DFNB1-related deafness, which was further divided into patients with CI activated before and after 1 year of life.

4.1 Functional variant rs3918242 of the MMP9 gene and auditory development

Out of the tested genetic variants of *MMP9* and *BDNF*, only rs3918242 *MMP9* showed significant association with auditory development in the subgroup with DFNB1-related deafness. At the 18th month after CI activation, carriers of C/C genotype scored, on average, 2.6 points higher than carriers of the C/T genotype (Table 1). This result is in line with results of our previous retrospective study, which reported the contribution of this polymorphism to LEAQ score over a 24 months follow-up in a cohort of 100 children with DFNB1-related deafness [44]. In the retrospective study, carriers of the C/C genotype scored higher than carriers of the C/T genotype, although the differences between their mean LEAQ scores did not reach significance. In the current analysis, we found statistically significant differences between mean LEAQ scores reached by the C/C and C/T genotype carriers at 18 months follow-up. Since there is no literature on the molecular regulation of neuroplasticity after deafness treatment, our results of testing associations of *MMP9* polymorphisms need to be read in the context of published data on how these polymorphisms behave in other clinical conditions involving neuroplasticity. We observed a cohort of CI-children, who, after activation of the CI and in response to stimulation delivered by the device, underwent a process of dynamic remodeling of cortical neuronal connections. The role of rs3918242 of *MMP9* in neuronal plasticity has only been studied so far in the context of aberrant plasticity, e.g., in schizophrenia or addictions [28,45-48]. Of note, several groups have reported inconsistent data in case control studies of rs3918242 of *MMP9* involvement in the clinical picture of these diseases. For example, Rybakowski et al. [28] reported that the C/C genotype of rs3918242 of *MMP9* was implicated in schizophrenia susceptibility, but this finding has not been reproduced in other schizophrenia studies [46,47]. However, a role for this polymorphism gene in schizophrenia has been confirmed in modifying the relationship between clinical severity and certain environmental risk factors [19]. Additionally, in an ethanol addiction study reported by Samochowiec et al. [48], the authors showed that the C/C genotype was more frequent in the families of alcoholics than in controls.

In our material, the impact of rs3918242 of *MMP9* on auditory development, among other genetic and clinical factors, was seen in a multiple regression model built around the older subgroup. The model indicated the significant effect of rs3918242 of *MMP9* on overall LEAQ score at follow-up (Table 3). For the average carrier of the C/C genotype, the average estimated LEAQ score was found to be higher by 6.49 points than for a carrier of the C/T genotype, a difference which can be converted into 7.7 months of delay in auditory development after cochlear implantation [38]. Clearly, the effect of follow-up interval has the highest impact on LEAQ score as predictor in the model, since it reflects the duration of CI use and the biological age of the implanted child, so it will inevitably rise from one follow-up interval to the next. It has already been well documented that the child's age when auditory development is measured is the strongest factor in shaping the outcome [2].

4.2 Plasma level of MMP-9 protein measured at cochlear implantation

In our material, plasma samples taken at cochlear implantation from carriers of less transcriptionally active C/C genotype of rs3918242 of *MMP9* showed lower levels of MMP-9 protein than samples from carriers of the more active C/T genotype. This pattern was repeated in the DFNB1-related deafness subgroup, although these differences did not reach statistical significance (respectively $p = 0.07$ and $p = 0.06$) *(Supplementary material).* Further analyses showed a significant negative correlation between the plasma level of MMP-9 protein measured at cochlear implantation with LEAQ score measured at the end-point observation (LEAQ_18) for (i) the whole study group; for (ii) the DFNB1-related deafness subgroup; and for (iii) the subgroup with DFNB1-related deafness and CI activation after 1 year of life ($p = 0.04$, rho $= -0.25$; $p = 0.005$, rho $= -0.4$; and $p = 0.01$, rho $= 0.5$, respectively) (Figs 1–3). These correlations indicate that a deaf child who at cochlear implantation has a lower MMP-9 protein plasma level, is predisposed to better auditory outcome after 18 months of speech and language rehabilitation. Only for the youngest group do we not see this trend.

Rs3918242 of *MMP9*, being a result of functional C>T substitution in the gene promoter region, exerts a critical effect on transcriptional activity [46,47]. This finding may be interpreted in line with data reported in our retrospective study, in which we did not find a significant association between rs3918242 of *MMP9* and auditory development for children implanted before their 1st birthday, contrary to children implanted after their 1st birthday [44]. However, this finding needs to be regarded with caution, since differences in MMP-9 protein plasma levels for carriers of the C/C and C/T genotypes did not reach significance. On the other hand, this age-dependent difference also supports our other conclusion, that there may be differences in molecular mechanisms underlying cognitive processing in very young children (implanted before and after their 1st birthday). Data reported in this paper suggest that activated pathways may not involve MMP-9 if the delivery of sensory stimuli takes place before the 1st year of life. Plasma levels of MMP-9_0 and BDNF_0 proteins were not significantly affected by the other functional variants mentioned (*Supplementary material).*

To date, we have not found any published protein data for plasma samples taken from a homogenous cohort of congenitally sensory-deprived patients. For this reason, and to gain more insight into the

molecular background of neural plasticity, we need to compare our results with reports from studies involving other physiological and pathological conditions. The role of MMP-9 in neuronal plasticity has already been well-studied, and its influence on this process has been documented in memory and learning and various pathological neuropsychiatric conditions, such as schizophrenia, addiction, or epilepsy [17,18,46,49]. A body of literature describes, for rodents, an important role for the MMP-9 protein in the critical plasticity period [20]. This molecule is mainly involved in the active structural and functional reorganization of excitatory synapses and dendritic spines, and is subject to multifactorial regulation at several levels, including gene expression, mRNA stability and localization (including translocation towards dendrites and synapses), protein production and release, and enzymatic activity [17,18,20,22,45,50]. Results of studies on *MMP9* knock-out mice have shown that the MMP-9 protein is critical for appetitive learning and memory formation [51]. Research on human schizophrenia patients shows that elevated MMP-9 protein levels are significantly correlated with cognitive decline, particularly in terms of language, fluency, and verbal and general memory [46,49,52,53].

Our data do not show the actual, temporal relation between MMP-9 protein levels in plasma and the phenotype. Changes in MMP-9 plasma levels may influence the phenotype. This has been indirectly observed in animal models, as well as in clinical studies on Fragile X Syndrome (FXS) children treated with the MMP-9 inhibitor minocycline [54,55,56]. FXS is due to a lack of FMRP (Fragile X Mental Retardation Protein), which is associated with alterations in the expression of MMP-9, and in animal models there is elevated levels of the protein in the hippocampus, which is lowered after minocycline administration. Early treatment (before the 4th week of life) with minocycline promotes the maturation of dendritic spines in vivo and in vitro, and relieves anxiety and improves cognition [54]. In human trials, authors report significant decreases in typical symptoms of FXS after minocycline administration (attention deficits, mood disorders, hyperactivity, cognition, and language fluency) [55].

4.3 Ratio of pro-BDNF/BDNF plasma levels measured at cochlear implantation

In the light of our current state of knowledge about the molecular background of neural plasticity and the role of BDNF in these processes, the apparent lack of involvement of BDNF in the results presented here is surprising [29,30,57,58]. We have found no significance of *BDNF* polymorphisms, nor a role for the protein in auditory development, and no correlation between pro-BDNF_0/BDNF_0 ratio and LEAQ scores. Nevertheless, a multiple regression model based on data from the DFNB1-related deafness subgroup over 18 months of observation has shown both follow-up interval and pro-BDNF_0/BDNF_0 ratio play a significant role in the auditory development of the implanted children (Table 2). Of course, in the model we find that follow-up interval, as in a regression model built using gene polymorphisms as predictors, is the most significant predictor. BDNF is a large molecule that is cleaved by proteases from pro-BDNF into the mature form and exerts a range of neurotrophic effects on neurons [36,58]. Animal studies demonstrate that MMP-9 may also play a role in converting the pro-form of BDNF into its mature form [35]. Interestingly, recent accumulating evidence suggests that pro-BDNF and BDNF may have opposite effects on neuronal plasticity [33,36,58,59]. Abnormalities in conversion of pro-BDNF to BDNF have already been postulated as helping to explain certain neuropathological processes underlying

various brain disorders like bipolar depression or epilepsy [33,35]. After applying the linear mixed-effect model methodology to our cohort of children with DFNB1-related deafness, we have found a progressive decrease in pro-BDNF_0/BDNF_0 ratio. Acting over the long neurodevelopmental process that occurs following a period of sensory deprivation, a change in ratio of 20 predisposes an implanted child to score 1 point higher in LEAQ (Table 2). However, we see a very wide range in the ratio of pro-BDNF_0/BDNF_0 in DFNB-1 related deafness subgroup (0.2 to 161.5, SD 29.4), so it is clear that the relation reflects a highly dynamic process.

4.4 Perspective

Our data should be interpreted with caution. However, they do provide an indication of children's capacity for successful speech and language rehabilitation after cochlear implantation. We have not isolated a biomarker of children who risk failure in speech and language rehabilitation, but we were able to point to a biochemical marker of good performers. Further research is needed to confirm this finding. However, broadening the pre-implant diagnostic panel of commercially available ELISA (Enzyme-linked Immunosorbent Assay) tests for MMP-9 plasma level would add considerable value and is easy to implement into clinical practice.

4.5 Limitations

This is the first attempt to shed light on the molecular machinery of neuroplasticity after cochlear implantation in congenital deafness treatment, and as such it has many limitations and should be subject to wide-ranging critique. An undeniable weakness of this study is the measurement tool for assessing language development – the LEAQ and, in particular, its subjective character. Moreover, the effect of environmental factors, like parental/maternal educational status and the parents' motivation to support the child through rehabilitation, is very difficult to control during such a study. We have followed the children only up to the 18th month after CI activation; further longitudinal observation would add valuable detail on linguistic competency. Another factor limiting the group homogeneity, but which was out of our control, is the degree of cross-modal cortical reorganisation before cochlear implantation. Despite a relatively short period of auditory deprivation in our patients, reorganisation could have already taken place and could have affected the outcome [60,16]. We used only a relatively small sample size, comprising subjects from the Polish population. Large-scale, multi-center studies incorporating subjects of different ethnicities are needed to see whether these results may be repeated more universally. Finally, both tested proteins are also involved in numerous other biological processes in the human body which are not connected with neuronal plasticity, and so the relations between protein plasma level and phenotype seen in our material may not be repeatable in cases where there are other health problems.

Declarations

Funding

Conflict of interest

The authors declare that there is no conflict of interests.

Availability of data

The data sets analyzed during this study are accessible on reasonable request.

Authors' contributions

Conceptualization: MM, LK, data curation: MM, formal analysis: MM, DO, funding acquisition: MM, investigation: MM, DO, methodology: MM, DO, MO, ER, resources: HS, MM, software: MM, supervision: LK, HS, validation: MM, DO, PHS, visualization: MM, DO, writing original draft: MM, writing review and editing: LK, DO, MO, MM.

Ethics approval

The study was designed and conducted according to the Declaration of Helsinki. It was reviewed and approved by the Bioethics Committee of the Institute of Physiology and Pathology of Hearing (no. IFPS:KB/13/2015).

Consent to participate and for publication

Parents or caregivers of all participants gave written informed consent.

References

1. Kral A., Kronenberger W. G., Pisoni D. B., O'Donoghue G. M., 2016. Neurocognitive factors in sensory restoration of early deafness: a connectome model. Lancet Neurolology 15(6):610–21. doi: 10.1016/S1474-4422(16)00034-X.

2. Niparko J., Tobey E. A., Thal D. J., Eisenbrg L. S., Wang N. Y., Quittner A. L., Fink N. E., CDaCI Investigative Team., 2010. Spoken language development in children following cochlear implantation JAMA. 303(15):1498–1506. doi: 10.1001/jama.2010.451.

3. De Raeve L., 2010. A longitudinal study on auditory perception and speech intelligibility in deaf children implanted younger than 18 months in comparison to those implanted at later ages. Otol Neurotol.

31(8):261–267. doi: 10.1097/MAO.0b013e3181f1cde3.

4. Fallon J. B., Irvine D. R. F., Shepherd R. K., 2009. Neural prostheses and brain plasticity *J Neural Eng*, 6(6):065008. doi: 10.1088/1741-2560/6/6/065008.

5. Houston D. M., Stewart J., Moberly A., Hollich G., Miyamoto R. T., 2012. Word learning in deaf children with cochlear implants: effects of early auditory experience. Dev Sci. 15:448–61. doi: 10.1111/j.1467-7687.2012.01140.x.

6. Oziębło D., Obrycka A., Lorens A., Skarżyński H., Ołdak M., 2020. Cochlear implantation outcome in children with DFNB1 *locus* pathogenic variants. J Clin Med. 9(1):228. doi: 10.3390/jcm9010228.

7. Abdurehim Y., Lehmann A., Zeitouni A. G., 2017. Predictive value of GJB2 mutation status for hearing outcomes of pediatric cochlear implantation. Otolaryngol Head Neck Surg. 157(1):16–24. doi: 10.1177/0194599817697054.

8. Shearer A. E., Eppsteiner R. W., Frees K., Tejani V., Sloan-Heggen C. M., Brown C., Abbas P, Dunn C., Hansen M. R., Gantz B. J., Smith R. J. H., 2017. Genetic variants in the peripheral auditory system significantly affect adult cochlear implant performance. *Hear Res.* 348:138–142. doi: 10.1016/j.heares.2017.02.008. Epub 2017 Feb 15.

9. Park J. H., Kim A. R., Han J. H., Kim S. D., Kim S. H., Koo J.-W., Oh S. H., Choi B. Y., 2017. Outcome of cochlear implantation in prelingually deafened children according to molecular genetic etiology. Ear Hear. 38(5):e316–e324. doi: 10.1097/AUD.0000000000000437.

10. Reinert J., Honegger F., Gurtler N., 2010. High homogeneity in auditory outcome of pediatric CI-patients with mutations in Gap-Junction-Protein Beta2. Intl J Pediatr Otorhinolaryngol. 74(7):791–5. doi: 10.1016/j.ijporl.2010.04.002.

11. Eppsteiner R. W., Shearer A. E., Hilderbrand M. S., DeLuca A. P., Haihong J., Dunn C. C., Black-Ziegelbein E. A., Casavant T. L., Braun T. A., Scheetz T. E., Scherer S. E., Hansen M. R., Ganz B. J., Smith R. J. H., 2012. Prediction of cochlear implant performance by genetic mutation: the spiral ganglion hypothesis *Hear Res.* 292(1–2):51–58. doi: 10.1016/j.heares.2012.08.007.

12. Angeli S. I., Suarez H., Lopez H., Balkany T., Liu X. Z., 2011. Influence on *DFNB1* status on expressive language in deaf children with cochlear implants. Otol Neurotol. 32: 1437–1443. doi: 10.1097/mao.0b013e31823387f9

13. Chen, J., Chen J., Zhu, Y., Liang, C., Zhao, H. B., 2014. Deafness induced by Connexin 26 (GJB2) deficiency is not determined by endocochlear potential (EP) reduction but is associated with cochlear developmental disorders. Biochem Biophys Res Commun. 448, 28–32. doi:10.1016/j.bbrc.2014.04.016.

14. Kikuchi T., Adams, J. C., Miyabe, Y., So, E., Kobayashi, T., 2000. Potassium ion recycling pathway via gap junction systems in the mammalian cochlea and its interruption in hereditary nonsyndromic

deafness. Med Electron Microsc. 33(2): 51–56. doi:10.1007/s007950070001.

16. Lee H.-J., Giraud A.-L., Kang E., Oh S.-H., Kang H., Kim C.-S., Lee D.-S., 2007. Cortical activity at rest predicts cochlear implantation outcome. Cereb Cortex. 17:909–917 doi:10.1093/cercor/bh1001.

17. Beroun A., Mitra S., Michaluk P, Pijet B., Stefaniuk M., Kaczmarek L., 2019. MMPs in learning and memory and neuropsychiatric disorders. Cell Mol Life Sci. 76(16):3207–3228. doi: 10.1007/s00018-019-03180-8.

18. Vafadari B., Salamian A., Kaczmarek L., 2016. MMP-9 in translation: from molecule to brain physiology, pathology, and therapy. J Neurochem. 139 Suppl 2:91–114. doi: 10.1111/jnc.13415.

19. McGregor N., Thompson N., O'Connell K.S., Emsley R., van der Merwe L., Warnich L., 2018. Modification of the association between antipsychotic treatment response and childhood adversity by MMP9 gene and its variants in a first-episode schizophrenia cohort. Psychiatry Res. 262:141–148. doi: 10.1016/j.psychres.2018.01.044.

20. Reinhard S. M., Razak K., Ethell I., 2015. A delicate balance: role of MMP9 in brain development and pathophysiology of neurodevelopmental disorders. Front Cell Neurosci. 9:280. doi: 10.3389/fncel.2015.00280.

21. Rivera S., Khrestchaitsky M., Kaczmarek L., Rosenberg G., Jaworski D. M., 2010. Metzincin proteases and their inhibitors: foes and friends in nervous system physiology? *J Neurosci*, 30(46):15337–57. doi: 10.1523/jneurosci.3467-10.2010.

22. Vandooren J., Van den Steen P. E., Opdenakker G., 2013. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. *Crit Rev Biochem Mol Biol*, 48(3):222–72. doi: 10.3109/10409238.2013.770819.

23. Ethel I. M., Ethel D. W., 2007. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res. 85(13):2913–2823. doi: 10.1002/jnr.21273.

24. Nagy V., Bozdagy O., Matynia A., Balcerzak M., Okulski P., Dzwonek J., Costa R. M., Silva A. J., Kaczmarek L., Huntley G., 2006. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci. 26(7):1923–34. doi: 10.1523/jneurosci.4359-05.2006.

25. Nagy V., Bozdagy O., Huntley W. H., 2007. The extracellular protease matrix metalloproteinase-9 is required by inhibitory avoidance learning and required for long term memory. Learn Mem. 14(10):655–64. doi: 10.1101/lm.678307.

26. Bozdagi O., Nagy V., Kwei K. T., Huntley G. W., 2007. In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity. J Neurophysiol. 98(1):334–44. doi:

10.1152/jn.00202.2007.

27. Okulski P., Jay T. M., Jaworski J., Duniec K., Dzwonek K., Dzwonek J., Konopacki F. A., Wilczynski G. M., Sanchez-Capelo A., Mallet J, Kaczmarek L., 2007. TIMP-1 abolishes MMP-9-dependent long-lasting long-term potentiation in the prefrontal cortex. Biol Psychiatry. 62(4):359–62. doi: 10.1016/j.biopsych.2006.09.012.

28. Rybakowski J. K., Skibińska M., Kapelski P, Kaczmarek L., Hauser J., 2009. Functional polymorphism of the matrix metalloproteinase-9 (MMP-9) gene in schizophrenia. Schizophr Res. 109(1–3):90–93. doi: 10.1016/j.schres.2009.02.005.

29. Bekinschtein P., Cammarota M., Medina J.H., 2014. BDNF and memory processing Neuropharmacology. Jan;76 Pt C:677–83. doi: 10.1016/j.neuropharm.2013.04.024.

30. Hariri A. R., Goldberg T. E., Mattay V. S., Kolachana B. S., Callicott J. H., Egan M. F., Weinberger D. R., 2003. BDNF val66met polymorphism affects human memory–related hippocampal activity and predicts memory performance. J Neurosci. 23(17):6690–6694. doi: 10.1523/jneurosci.23-17-06690.2003.

31. Leal G., Comprido D, Duarte C. B., 2014. BDNF-induced local protein synthesis and synaptic plasticity. Neuropharmacology. 76 Pt C:639–56. doi: 10.1016/j.neuropharm.2013.04.005.

32. Zagrebelsky M., Korte M., 2014. Form follows function: BDNF and its involvement in sculpting the function and structure of synapses. Neuropharmacology. 76:628–638, doi: 10.1016/j.neuropharm.2013.05.029.

33. Sodersten K., Palsson E., Ishima T., Funa K., Landen M., Hashimoto K., Agren H., 2014. Abnormality in serum levels of mature BDNF and its precursor proBDNF in mood stabilized patients with bipolar disorder: a study of two independent cohorts. J Affect Disord. 160:1–9. doi: 10.1016/j.jad.2014.01.009.

34. Siuda J., Patalong-Ogiewa M., Żmuda W., Targosz-Gajniak M., Niewiadomska E., Matuszek I., Jędrzejowska-Szypułka H., Lewin-Kowalik J, Rudzińska-Bar M., 2017. Cognitive impairment and BDNF serum levels. Neurol Neurochir Pol. 51(1):24–32. doi: 10.1016/j.pjnns.2016.10.001.

35. Mizoguchi H., Nakade J., Tachibana M., Ibi D., Someya E., Koike H., Kamei H., Nabeshima T., Itohara S., Takuma K., Sawada M., Sato J., Yamada K., 2011. Matrix metalloproteinase-9 contributes to kindled seizure development in pentylenetetrazole-treated mice by converting pro-BDNF to mature BDNF in the hippocampus. J Neurosci. 31(36):12963–71. doi: 10.1523/jneurosci.3118-11.2011.

36. Hashimoto K., 2010. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci. 64(4):341–57. doi: 10.1111/j.1440-1819.2010.02113.x.

37. Weichbold V., Tsiakpini L., Coninx F., D'Haese P, 2005. Development of a parent questionnaire for assessment of auditory behaviour of infants up to two years of age. Laryngorhinootologie, 84(5):328–

334. doi: [10.1055/s-2004-826232](10.1055/s-2004-826232).

38. Obrycka A., Padilla Garcia J. P., Pankowska A., Lorens A., Skarżynski H., 2009. Production and evaluation of a Polish version of the LittlEars questionnaire for the assessment of auditory development in infants. Int J Pediatr Otorhinolaryngol. 73(7):1035–1042. doi: 10.1016/j.ijporl.2009.04.010.

39. Obrycka A., Lorens A., Padilla J. L., Piotrowska A., Skarżyński H., 2017. Validation of the LittlEARS Auditory Questionnaire in cochlear implanted infants and toddlers. Int J Pediatr Otorhinolaryngol .93:107–116. doi: 10.1016/j.ijporl.2016.12.024.

40. Coninx F., Weichbold V., Tsiakpini L., Autrique E., Bescond G., Tamas L., Compernol A., Georgescu M., Koroleva I., Le Maner-Idrissi G., Liang W., Madell J., Miić B., Obrycka A., Pankowska A., Pascu A., Popescu R., Radulescu L., Reuhamaki T., Rouev P., Kabatova Z., Spitzer J., Thodi Ch., Varzic F., Vischer M., Wang L., Zavala JS., Brachmaier J., 2009. Validation of the LittlEARS Auditory Questionnaire in children with normal hearing. Int J Pediatr Otorhinolaryngol, 73(12):1761–1768. doi: 10.1016/j.ijporl.2009.09.036.

41. Geal-Dor M., Jbarah R., Meilijson S., Adelman C., Levi H., 2011. The Hebrew and the Arabic version of the LittlEARS Auditory Questionnaire for the assessment of auditory development: Results in normal hearing children and children with cochlear implants. Int J Pediatr Otorhinolaryngol. 75(10):1327–1332. doi: 10.1016/j.ijporl.2011.07.030.

42. Wanga L., Sun X., Liang W., Chen J., Zheng W., 2013. Validation of the Mandarin version of the LittlEARS Auditory Questionnaire. Int J Pediatr Otorhinolaryngol. 77(8):1350–1354. doi: 10.1016/j.ijporl.2013.05.033.

43. García Negro A. S., Padilla García J. L., Sainz Quevedo M., 2016. Production and evaluation of a Spanish version of the LittlEARS Auditory Questionnaire for the assessment of auditory development in children. Int J Pediatr Otorhinolaryngol. 83:99–103. doi: 10.1016/j.ijporl.2016.01.021.

44. Matusiak M., Oziębło D., Obrycka A., Ołdak M., Kaczmarek L., Skarżyński P, Skarżyński H., 2021. Functional polymorphism of MMP9 and BDNF as a potential biomarker of auditory plasticity in prelingual deafness treatment with cochlear implantation: a retrospective cohort analysis. Trends Hear. Jan-Dec 2021;25:23312165211002140. doi: 10.1177/23312165211002140.

45. Lepeta K., Purzycka K. J., Pachulska-Wieczorek K., Mitjans M., Begemann M., Vafadari B., Bijata K., Adamiak R. W., Ehrenreich H., Dziembowska M., Kaczmarek L., 2017. A normal genetic variation modulates synaptic MMP-9 protein levels and the severity of schizophrenia symptoms. EMBO Mol Med., 9(8):1100–1116. doi: 10.15252/emmm.201707723.

46. Ali F. T., Abd El-Azeem E. M., Hamed M. A., Ali M. A. M., Abd Al-Kader N. M., Hassan E. A., 2017. Redox dysregulation, immuno-inflammatory alterations and genetic variants of BDNF and MMP-9 in schizophrenia: pathophysiological and phenotypic implications. Schizophr Res. 188:98–109. doi: 10.1016/j.schres.2017.01.016.

47. Xia Q.-R., Zhang C., Liang J., Xu Y.-Y., 2019. The association of functional polymorphism of matrix metalloproteinase-9 gene (rs3918242) with schizophrenia: a meta-analysis. Int J Psychiatry Clin Pract. 23(3):207–214. doi: 10.1080/13651501.2019.1581895.

48. Samochowiec A., Grzywacz A., Kaczmarek L., Bienkowski P., Samochowiec J., Mierzejewski P., Preuss U. W., Grochans E., Ciechanowicz A., 2010. Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene in alcohol dependence: family case control study. Brain Res. 1327: 103–106. doi: 10.1016/j.brainres.2010.02.072

49. Kudo N., Yamamori H., Ishima T., Nemoto K., Yasuda Y., Fujimoto M., Azechi H., Niitsu T., Numata S., Ikeda M., Iyo M., Ohmori T., Fukunaga M., Watanabe Y., Hashimoto K., Hasimoto R., 2020. Plasma levels of matrix metalloproteinase-9 (MMP-9) are associated with cognitive performance in patients with schizophrenia. Neuropsychopharmacol Rep. Jun;40(2):150-156. doi: 10.1002/npr2.12098.

50. Michaluk P, Wawrzyniak M., A lot P., Szczot M., Wyrembek P., Mercik K., Medvedev N., Wilczek E., De Roo M., Zuschratter W., Muller D., Wilczynski G. M., Mozrzymas J. W., Stewart M. G., Kaczmarek L., Wlodarczyk J., 2011. Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology. J Cell Sci. Oct 1;124(Pt 19):3369-80. doi: 10.1242/jcs.090852.

51. Knapska E., Lioudyno V., Kiryk A., Mikosz M., Górkiewicz T., Michaluk P., Gawlak M., Chaturvedi M., Mochol G., Balcerzyk M., Wojcik D. K., Wilczynski G. M., Kaczmarek L., 2013. Reward learning requires activity of matrix metalloproteinase-9 in the central amygdala. J Neurosci. 33(36): 14591–14600. doi: 10.1523/JNEUROSCI.5239-12.2013.

52. Keshri N., Nandeesha H., Rajappa M., Menon V., 2021. Matrix metalloproteinase-9 increases the risk of cognitive impairement in schizophrenia. Nord J Psychiatry. Feb;75(2):130-134. doi: 10.1080/08039488.2020.1808901.

53. Yamamori H., Hashimoro R., Ishima T., Kishi F., Yasuda Y., Ohi K., Fujimoto M., Umeda-Yanp S., Ito A., Hashimoto K., Takeda M., 2013. Plasma levels of matire brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine. Neurosci Lett Nov 27;556:37-41. doi: 10.1016/j.neulet.2013.09.059.

54. Bilousova T.V., Dansie L., Ngo M., Aye J., Charles J. R., Ethell D. W., Ethell I. M., 2009. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet. 46:94–102. doi: 10.1136/jmg.2008.061796.

55. Leigh M. J., Nguyen D. V., Mu Y., Winarni T. I., Schneider A., Chechi T., Polussa J., Dpucet P., Tassone F., Rivera S. M., Hessl D., Hagerman R. J., 2013. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with Fragile X Syndrome. J Dev Behav Pediatr. 34(3): 147–155. doi: 10.1097/DBP.0b013e318287cd17.

56. Schenider A., Leigh M. J., Adams P., Nanakul R., Chechi T., Olichney J., Hagerman R., Hessl D., 2013. Electrocortical changes associated with minocycline treatment in fragile X syndrome. J Psychopharmacol. 27(10): 956–963. doi: 10.1177/0269881113494105.

57. Brunoni A. R., Lopes M., Fregni F., 2008. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol. 11(8):1169–80. doi: 10.1017/S1461145708009309.

58. Yoshida T., Ishikawa M., Niitsu T., Nakazato M., Watanabe H., Shiraishi T., Shiina A., Hashimoto T., Kanahara N., Hasegawa T., Enohara M., Kimura T., Iyo M., Hashimoto K., 2012. Decreased serum level of mature Brain-Derived Neurotrophic Factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder. PLoS One. 7(8):e42676. doi: 10.1371/journal.pone.0042676.

59. Yoshimura R., Kishi T., Hori H., Atake K., Katsuki A., Nakano-Umene W., Ikenouchi-Sugita A., Uwata N., Nakamura J., 2014. Serum proBDNF/BDNF and response to fluvoxamine in drug naïve first-episode major depressive disorder patients. Ann Gen Psychiatry. 13:19. doi: 10.1186/1744-859X-13-19.

60. Glennon E., Svirsky M. A., Froemke R. C., 2020. Auditory cortical plasticity in cochlear implant users. Curr Opin Neurobiol. 60:108–114. doi: 10.1016/j.conb.2019.11.003.

Tables

Table 1. Association of auditory development measures (LEAQ score) with *MMP9* and *BDNF* variants in all tested intervals in the subgroup with DFNB1-related deafness (N=40). * indicates $p<0.05$.

	follow-up interval	mean LEAQ score (SD)	p-value
MMP9 rs3918242			
C/C(30) C/T(10)	0	6.5 (7.1) / 2.5 (3.9)	0.06
C/C(30) C/T(10)	8	27.8 (4.6) / 25.3 (8.3)	0.5
C/C(30) C/T(10)	18	33.2 (2.7) / 30.6 (3.9)	0.03[*]
MMP9 rs2234681			
<20/<20 (11) ≥20/≥20(6)	0	7.1 (9) / 7.3 (8)	0.7
<20/<20 (11) ≥20/≥20(6)	8	29.5(3.4) / 25.8 (6.2)	0.2
<20/<20 (11) ≥20/≥20(6)	18	33 (2.9) / 31.7 (4.4)	0.7
<20/<20 (11) <20/≥20 (23)	0	7.1 (9) / 4.3 (4.9)	0.4
<20/<20 (11) <20/≥20 (23)	8	29.5 (3.4) / 26.4 (6.4)	0.2
<20/<20 (11) <20/≥20 (23)	18	33 (2.9) / 32.6 (3.1)	1.0
<20/≥20 (23) ≥20/≥20(6)	0	4.3 (4.9) / 7.3 (8)	0.2
<20/≥20 (23) ≥20/≥20(6)	8	26.4 (6.4) / 25.8 (6.2)	0.8
<20/≥20 (23) ≥20/≥20(6)	18	32.6 (3.1) / 31.7 (4.4)	0.8
MMP9 rs20544			
C/T(21) T/T(11)	0	4.7 (4.9) / 8.5 (9.1)	0.3
C/T(21) T/T(11)	8	26.5 (6.2) / 29.6 (3.4)	0.4
C/T(21) T/T(11)	18	32.62 (3.1) / 33.3 (2.9)	0.3
C/C(8) T/T(11)	0	3.6 (6.3) / 8.5 (9.1)	0.2
C/C(8) T/T(11)	8	25.6 (6.7) / 29.6 (3.4)	0.1
C/C(8) T/T(11)	18	32.5 (3.1) / 33.3 (2.9)	1.0
C/C(8) C/T(21)	0	3.6 (6.3) / 4.7 (4.9)	0.6
C/C(8) C/T(21)	8	25.6 (6.7) / 26.5 (6.2)	0.7
C/C(8) C/T(21)	18	32.5 (4) / 32.2 (3.1)	0.4
BDNF rs6265			
Val/Val (29) Val/Met (11)	0	4.4 (5.4) / 8.4 (9)	0.1
Val/Val (29) Val/Met (11)	8	27.1 (5) / 27.4 (7.7)	0.4
Val/Val (29) Val/Met (11)	18	32.7 (3) / 32.2 (3.7)	0.8

Table 2. Summary of linear mixed-effect model for LEAQ score in the DFNB1-related deafness subgroup. Estimates show the impact of significant predictors (marked by asterisks). $R^2 = 0.72$. SE, Standard Error

Predictors	Dependent variable: LEAQ, (SE)	p-value
Follow-up interval (months)	1.465[***] (0.086)	<0.001
Sex	0.863 (1.301)	0.508
BDNF_0	0.245 (0.348)	0.483
MMP9_0	−0.008 (0.007)	0.256
Ratio pro-BDNF_0/BDNF_0	−0.049[*] (0.024)	<0.05
Age at CI activation	0.008 (0.006)	0.183
Constant	7.385[*] (2.936)	<0.05
Observations	120	
Log likelihood	−411.014	
Akaike info criterion	840.028	
Bayesian info criterion	865.115	

Table 3. Summary of linear mixed-effect model for LEAQ score in the subgroup with DFNB1-related deafness and CI activation after 1 year. Estimates show the impact of significant predictors (marked by asterisks). $R^2 = -0.7$. SE, Standard Error.

| Predictors	Dependent variable: LEAQ, (SE)	p-value
Follow-up interval (months)	1.346*** (0.121)	<0.001
Sex	0.231 (2.100)	0.913
BDNF rs6265	1.931 (2.330)	0.410
MMP9 rs2234681 = <20, ≥20	5.390 (5.746)	0.352
MMP9 rs2234681 = ≥20, ≥20	−1.271 (3.684)	0.731
MMP9 rs20544	−8.156 (5.286)	0.128
MMP9 rs3918242	−6.494 (2.830)*	<0.05
Age at CI activation	−0.001 (0.010)	0.929
Constant	13.209* (5.963)	<0.05
Observations	66	
Log likelihood	−212.487	
Akaike info criterion	446.974	
Bayesian info criterion	471.060	

Figures

Figure 1

Correlation between plasma levels of MMP-9_0 and auditory development measurements at the 18th month after CI-activation (LEAQ_18) in the study group.

Figure 2

Correlation between MMP-9_0 plasma level and LEAQ score at the 18th month after CI-activation (LEAQ_18) in the DFNB1-related deafness subgroup.

Figure 3

Correlation between MMP-9_0 and auditory development measurements at 18 months after CI activation (LEAQ_18) in the subgroup with DFNB1-related deafness and CI activation after 1 year old.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- supplementarymaterial.docx